Literature DB >> 19240994

Reirradiation of multiple brain metastases with helical tomotherapy. A multifocal simultaneous integrated boost for eight or more lesions.

Florian Sterzing1, Thomas Welzel, Gabriele Sroka-Perez, Kai Schubert, Jürgen Debus, Klaus K Herfarth.   

Abstract

BACKGROUND AND
PURPOSE: : Recurrent brain metastases or new brain lesions after whole-brain radiotherapy represent a therapeutic challenge. While several treatment methods for single or few lesions have been described, options for multiple lesions are limited. This case report is intended to show an approach of whole-brain reirradiation with a simultaneous multifocal integrated boost using helical tomotherapy. Technique, feasibility, and acute side effects are presented. PATIENTS AND METHODS: : Two patients with multiple relapsed brain metastases (eight and eleven lesions) were reirradiated after previous whole-brain radiotherapy (total dose of 40 Gy 18 months before). Whole-brain reirradiation was performed using helical tomotherapy with a total dose of 15 Gy (single dose 1.5 Gy) and a multifocal simultaneous integrated boost with a total dose of 30 Gy (single dose 3 Gy) to the brain lesions. The boost planning target volume was delineated around the lesions visible on MRI plus a 2-mm margin. Follow-up of these patients was 6 and 12 months.
RESULTS: : Radiation plans with excellent conformity and homogeneity were obtained. High dose exposure to normal brain tissue was kept minimal. Mean radiation time was 13 min. The only acute side effect observed was a mild headache over 2 days at the end of treatment. So far, no further side effects and no signs of recurrence have been observed.
CONCLUSION: : Helical tomotherapy offers new treatment options for the reirradiation of multiple brain metastases. The number of cases treated with the described protocol is very limited but it is considered a promising option for patients that have responded well to the initial radiotherapy and are in a good performance status.

Entities:  

Mesh:

Year:  2009        PMID: 19240994     DOI: 10.1007/s00066-009-1971-2

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  31 in total

Review 1.  Reirradiation for recurrent brain metastases: an overview.

Authors:  S Höcht; T Wiegel; W Hinkelbein
Journal:  Front Radiat Ther Oncol       Date:  1999

2.  Tomotherapy planning of small brain tumours.

Authors:  Slav Yartsev; Tomas Kron; Luca Cozzi; Antonella Fogliata; Glenn Bauman
Journal:  Radiother Oncol       Date:  2005-01       Impact factor: 6.280

3.  Feasibility of cranio-spinal axis radiation with the Hi-Art tomotherapy system.

Authors:  José A Peñagarícano; Nikos Papanikolaou; Yulong Yan; Emad Youssef; Vaneerat Ratanatharathorn
Journal:  Radiother Oncol       Date:  2005-07       Impact factor: 6.280

4.  Dosimetric comparisons of helical tomotherapy treatment plans and step-and-shoot intensity-modulated radiosurgery treatment plans in intracranial stereotactic radiosurgery.

Authors:  Chunhui Han; An Liu; Timothy E Schultheiss; Richard D Pezner; Yi-Jen Chen; Jeffrey Y C Wong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-06-01       Impact factor: 7.038

5.  IGRT with helical tomotherapy--effort and benefit in clinical routine.

Authors:  Florian Sterzing; Klaus Herfarth; Juergen Debus
Journal:  Strahlenther Onkol       Date:  2007-12       Impact factor: 3.621

6.  EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force.

Authors:  R Soffietti; P Cornu; J Y Delattre; R Grant; F Graus; W Grisold; J Heimans; J Hildebrand; P Hoskin; M Kalljo; P Krauseneck; C Marosi; T Siegal; C Vecht
Journal:  Eur J Neurol       Date:  2006-07       Impact factor: 6.089

Review 7.  Brain metastases from breast cancer: management approach.

Authors:  Tabassum Wadasadawala; Sudeep Gupta; Vaishali Bagul; Namrata Patil
Journal:  J Cancer Res Ther       Date:  2007 Jul-Sep       Impact factor: 1.805

8.  Helical tomotherapy as a new treatment technique for whole abdominal irradiation.

Authors:  Nathalie Rochet; Florian Sterzing; Alexandra Jensen; Julien Dinkel; Klaus Herfarth; Kai Schubert; Michael Eichbaum; Andreas Schneeweiss; Christof Sohn; Juergen Debus; Wolfgang Harms
Journal:  Strahlenther Onkol       Date:  2008-03       Impact factor: 3.621

9.  Hypofractionated stereotactic radiotherapy for brain metastases--results from three different dose concepts.

Authors:  Antje Fahrig; Oliver Ganslandt; Ulrike Lambrecht; Gerhard Grabenbauer; Gabriele Kleinert; Rolf Sauer; Klaus Hamm
Journal:  Strahlenther Onkol       Date:  2007-11       Impact factor: 3.621

10.  Stereotactic radiosurgical treatment of cerebral metastases arising from breast cancer.

Authors:  Serap Akyurek; Eric L Chang; Anita Mahajan; Samuel J Hassenbusch; Pamela K Allen; Leni A Mathews; Almon S Shiu; Moshe H Maor; Shiao Y Woo
Journal:  Am J Clin Oncol       Date:  2007-06       Impact factor: 2.339

View more
  23 in total

1.  18F-FET-PET-based dose painting by numbers with protons.

Authors:  Mark Rickhey; Zdenek Morávek; Christoph Eilles; Oliver Koelbl; Ludwig Bogner
Journal:  Strahlenther Onkol       Date:  2010-05-21       Impact factor: 3.621

Review 2.  Whole-brain radiation therapy in breast cancer patients with brain metastases.

Authors:  Cyrus Chargari; François Campana; Jean-Yves Pierga; Lionel Védrine; Damien Ricard; Sylvestre Le Moulec; Alain Fourquet; Youlia M Kirova
Journal:  Nat Rev Clin Oncol       Date:  2010-07-13       Impact factor: 66.675

3.  Radiotherapy for oligometastatic disease in patients with spinal cord compression (MSCC) from relatively radioresistant tumors.

Authors:  Katja Freundt; Thekla Meyners; Amira Bajrovic; Hiba Basic; Johann H Karstens; Irenaeus A Adamietz; Volker Rudat; Steven E Schild; Juergen Dunst; Dirk Rades
Journal:  Strahlenther Onkol       Date:  2010-03-26       Impact factor: 3.621

Review 4.  kV cone-beam CT-based IGRT: a clinical review.

Authors:  Judit Boda-Heggemann; Frank Lohr; Frederik Wenz; Michael Flentje; Matthias Guckenberger
Journal:  Strahlenther Onkol       Date:  2011-04-26       Impact factor: 3.621

5.  Design and implementation of a "cheese" phantom-based Tomotherapy TLD dose intercomparison.

Authors:  Hans Schiefer; Konrad Buchauer; Simon Heinze; Guido Henke; Ludwig Plasswilm
Journal:  Strahlenther Onkol       Date:  2015-06-19       Impact factor: 3.621

6.  [Integration of the radiotherapy irradiation planning in the digital workflow].

Authors:  F Röhner; M Schmucker; K Henne; F Momm; G Bruggmoser; A-L Grosu; H Frommhold; F E Heinemann
Journal:  Strahlenther Onkol       Date:  2012-12-20       Impact factor: 3.621

7.  Hematogenous metastases in patients with Stage I or II endometrial carcinoma.

Authors:  Paweł Blecharz; Krzysztof Urbański; Anna Mucha-Małecka; Krzysztof Małecki; Marian Reinfuss; Jerzy Jakubowicz; Piotr Skotnicki
Journal:  Strahlenther Onkol       Date:  2011-11-17       Impact factor: 3.621

8.  Whole-brain radiotherapy combined with surgery or stereotactic radiotherapy in patients with brain oligometastases: long-term analysis.

Authors:  Giuseppe Roberto D'Agostino; Rosa Autorino; Angelo Pompucci; Maria Carmen De Santis; Stefania Manfrida; Giuseppe Di Lella; Giovanna Mantini; Vincenzo Frascino; Silvia Chiesa; Alessio Albanese; Nicola Dinapoli; Luigi Azario; Alba Fiorentino; Vincenzo Valentini; Carmelo Anile; Mario Balducci
Journal:  Strahlenther Onkol       Date:  2011-06-28       Impact factor: 3.621

9.  Superiority of conventional intensity-modulated radiotherapy over helical tomotherapy in locally advanced non-small cell lung cancer. A comparative plan analysis.

Authors:  C Song; H Pyo; J Kim; Y K Lim; W C Kim; H J Kim; D W Kim; K H Cho
Journal:  Strahlenther Onkol       Date:  2012-08-17       Impact factor: 3.621

10.  Semi-robotic 6 degree of freedom positioning for intracranial high precision radiotherapy; first phantom and clinical results.

Authors:  Jürgen Wilbert; Matthias Guckenberger; Bülent Polat; Otto Sauer; Michael Vogele; Michael Flentje; Reinhart A Sweeney
Journal:  Radiat Oncol       Date:  2010-05-26       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.